版本:
中国

BRIEF-Mimedx urges FDA to reconsider draft guidances

Sept 15 Mimedx Group Inc :

* Mimedx says continues to believe that its marketing of its products as section 361 hct/ps is consistent with applicable statutes and regulations

* Mimedx urges FDA to reconsider draft guidances during hearing

* Says urged FDA to reconsider its draft guidances on "minimal manipulation" and homologous use of human cells

* Says "draft guidances cannot lawfully be adopted in their current form" Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐